Abstract:Targeted protein degradation (TPD) technology has gradually become widespread in the past 20 years, which greatly boosts the development of disease treatment. Contrary to small inhibitors that act on protein kinases, transcription factors, ion channels, and other targets they can bind to, targeted protein degraders could target "undruggable targets" and overcome drug resistance through ubiquitin–proteasome pathway (UPP) and lysosome pathway. Nowadays, some bivalent degraders such as proteolysis-targeting chimeras (PROTACs) have aroused great interest in drug discovery, and some of them have successfully advanced into clinical trials. In this review, to better understand the mechanism of degraders, we elucidate the targeted protein degraders according to their action process, relying on the ubiquitin–proteasome system or lysosome pathway. Then, we briefly summarize the study of PROTACs employing different E3 ligases. Subsequently, the effect of protein of interest (POI) ligands, linker, and E3 ligands on PROTAC degradation activity is also discussed in detail. Other novel technologies based on UPP and lysosome pathway have been discussed in this paper such as in-cell click-formed proteolysis-targeting chimeras (CLIPTACs), molecular glues, Antibody-PROTACs (Ab-PROTACs), autophagy-targeting chimeras, and lysosome-targeting chimeras. Based on the introduction of these degradation technologies, we can clearly understand the action process and degradation mechanism of these approaches. From this perspective, it will be convenient to obtain the development status of these drugs, choose appropriate degradation methods to achieve better disease treatment and provide basis for future research and simultaneously distinguish the direction of future research efforts.

Bifunctional Compounds as Molecular Degraders for Integrin-Facilitated Targeted Protein Degradation

PROTACs: an Emerging Targeting Technique for Protein Degradation in Drug Discovery

Targeted protein degradation via intramolecular bivalent glues

A co-assembly platform engaging macrophage scavenger receptor A for lysosome-targeting protein degradation

Harnessing the Lysosomal Sorting Signals of the Cation-Independent Mannose-6-Phosphate Receptor for Targeted Degradation of Membrane Proteins

Peptide-Mediated Small Molecule Lysosome-Targeting Chimeras for Targeted Degradation of Membrane and Intracellular Proteins

A Kinetic Scout Approach Accelerates Targeted Protein Degrader Development

ByeTAC: Bypassing an E3 Ligase for Targeted Protein Degradation

Lysosome Targeting Chimaeras for Glut1-Facilitated Targeted Protein Degradation

Bifunctional small molecules that mediate the degradation of extracellular proteins

A plug-and-play monofunctional platform for targeted degradation of extracellular proteins and vesicles

Development of Integrin Targeting Chimeras (ITACs) for the Lysosomal Degradation of Extracellular Proteins

A Novel Lysosome Targeting Chimera for Targeted Protein Degradation via Split-and-Mix Strategy

Molecular glue-mediated targeted protein degradation: A novel strategy in small-molecule drug development

Development of Integrin-Facilitated Bispecific Aptamer Chimeras for Membrane Protein Degradation

Bifunctional Peptide Nanofibrils for Targeted Protein Degradation.

Recent advances in targeted protein degraders as potential therapeutic agents

Insulin-like Growth Factor 2-Tagged Aptamer Chimeras (ITACs) Modular Assembly for Targeted and Efficient Degradation of Two Membrane Proteins

A covalent BTK ternary complex compatible with targeted protein degradation

Targeted protein degradation: from mechanisms to clinic

DCAF16-Based Covalent Handle for the Rational Design of Monovalent Degraders